Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22500701 | 0.98 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL22500789 | 0.98 | LMNA (0.42) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL22500751 | 0.96 | LMNA (0.41) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| Iodide SCHEMBL14778058 | 0.94 | LMNA (0.39) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| Bromide SCHEMBL14779567 | 0.94 | LMNA (0.39) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| Hydrochloric Acid SCHEMBL14779149 | 0.94 | LMNA (0.39) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL3812431 | 0.93 | ALDH1A1 (0.38) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL3813544 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL22500693 | 0.91 | ALDH1A1 (0.36) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL16178618 | 0.89 | NPC1 (0.35) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090242414-A1 | ELECTRONCHEMICAL DEPOSITION OF TANTALUM AND/OR COPPER IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | US | claimed |
| EP-1951934-B1 | ELECTROCHEMICAL DEPOSITION OF SELENIUM IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2009-08-19 | — | — | EP | claimed |
| US-20080210566-A1 | Electrochemical Deposition of Selenium in Ionic Liquids | MERCK PATENT GESELLSCHAFT (DE) | 2008-09-04 | — | — | US | claimed |
| EP-1951934-A1 | ELECTROCHEMICAL DEPOSITION OF SELENIUM IN IONIC LIQUIDS | Merck Patent GmbH (DE) | 2008-08-06 | — | — | EP | claimed |
| EP-1831433-A2 | ELECTROCHEMICAL DEPOSITION OF TANTALUM AND/OR COPPER IN IONIC LIQUIDS | Merck Patent GmbH (DE) | 2007-09-12 | — | — | EP | claimed |
| WO-2007039035-A1 | ELECTROCHEMICAL DEPOSITION OF SELENIUM IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2007-04-12 | — | — | WO | claimed |
| WO-2006061081-A2 | ELECTROCHEMICAL DEPOSITION OF TANTALUM AND/OR COPPER IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2006-06-15 | — | — | WO | claimed |
| US-20260108600-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250041239-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC (US) | 2025-02-06 | — | — | US | disclosed |
| US-12109303-B2 | Orally dissolving antimicrobial film compositions and methods of their use | ISHA Therapeutics LLC (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024076715-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240016735-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230330012-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | ISHA Therapeutics LLC | 2023-10-19 | — | — | US | disclosed |
| US-20090242414-A1 | ELECTRONCHEMICAL DEPOSITION OF TANTALUM AND/OR COPPER IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| EP-1951934-B1 | ELECTROCHEMICAL DEPOSITION OF SELENIUM IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080210566-A1 | Electrochemical Deposition of Selenium in Ionic Liquids | MERCK PATENT GESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1951934-A1 | ELECTROCHEMICAL DEPOSITION OF SELENIUM IN IONIC LIQUIDS | Merck Patent GmbH (DE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1831433-A2 | ELECTROCHEMICAL DEPOSITION OF TANTALUM AND/OR COPPER IN IONIC LIQUIDS | Merck Patent GmbH (DE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007039035-A1 | ELECTROCHEMICAL DEPOSITION OF SELENIUM IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006061081-A2 | ELECTROCHEMICAL DEPOSITION OF TANTALUM AND/OR COPPER IN IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016735-A1 | IONIC LIQUIDS FOR DRUG DELIVERY | SLCO4C1, SLC47A1, ABCB11 | SMN1; SMN2 319/4885LMNA 725/4885ALDH1A1 898/4885 |
| US-20260108600-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED IONIC LIQUID ADJUVANTS | ICOS, ICOSLG, TLR9 | SMN1; SMN2 1005/4885LMNA 3035/4885ALDH1A1 4423/4885 |
| US-20250041239-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | RAB5IF, CGAS, APOB | SMN1; SMN2 2784/4885LMNA 3264/4885ALDH1A1 2777/4885 |
| US-20230330012-A1 | ORALLY DISSOLVING ANTIMICROBIAL FILM COMPOSITIONS & METHODS OF THEIR USE | RAB5IF, CGAS, APOB | SMN1; SMN2 2784/4885LMNA 3264/4885ALDH1A1 2777/4885 |
| US-12109303-B2 | Orally dissolving antimicrobial film compositions and methods of their use | RAB5IF, APOB, ERG28 | SMN1; SMN2 2466/4885LMNA 3506/4885ALDH1A1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.